Cutaneous T-Cell lymphoma Market: Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight | Celgene, Galderma, Innate Pharma, Eisai Inc., Novartis and Others.

July 07 19:42 2021
Cutaneous T-Cell lymphoma Market: Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight | Celgene, Galderma, Innate Pharma, Eisai Inc., Novartis and Others.

Cutaneous T-Cell lymphoma Market

Cutaneous T-cell lymphoma (CTCL) is a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors; this group consist of the most common types of skin lymphoma. Furthermore, more than 3 out of every 4 skin lymphomas diagnosed are CTCLs and often appear as eczema-like skin rashes and can affect widespread parts of the body.

 

DelveInsight’s “Cutaneous T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Cutaneous T-Cell Lymphoma(CTCL), historical and forecasted epidemiology as well as the Cutaneous T-Cell Lymphoma (CTCL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of the CTCL Market Report are:

  • The CTCL therapeutic market in the seven major markets was found to be USD 488.77 million in 2018 and is expected to increase during the forecast period.
  • As per Delveinsight’s estimates, the total incident population of cutaneous T-cell lymphomas in the 7MM was 7,447 in 2018.
  • According to Delveinsight’s estimates, the highest incident cases of this disease were observed in the United States, which accounted for approximately 44.83% of the total incident cases.
  • Japan had 1,267 cases in 2018, which accounted for approximately 17% of the total 7MM incident cases of CTCL.
  • In 2018, there were 1,778 male and 1,571 female incident cases of CTCL estimated in the United States.
  • SGX301 (Soligenix), Tislelizumab (BeiGene) Cobomarsen (miRagen Therapeutics, Inc.), Resminostat (4SC), and E777 (Eisai) are the other drugs in the pipeline. SGX301 and E777 have also received Orphan Designation from the FDA.

 

Request For Sample Page: https://www.delveinsight.com/sample-request/cutaneous-t-cell-lymphoma-ctcl-market

 

“Cutaneous T-cell Lymphoma (CTCL) market share in 2019 was the highest for the United States followed by EU5 (Germany, France, Italy, Spain & UK) and Japan.”

 

Cutaneous T-Cell Lymphoma treatment depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The FDA approved drugs include Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex (methoxsalen), Targretin (bexarotene) and Zolinza (vorinostat).

A myriad of scheduled launches of emerging therapies within the forecast period (2018-30) is expected to change the dynamics of the CTCL market. The speculation garnered on the basis of the positive results exhibited by the ongoing clinical trials with respect to the drugs under development.

 

Some of CTCL Companies are:

  • Celgene
  • Galderma
  • Innate Pharma
  • Eisai Inc.
  • Novartis Pharmaceuticals
  • Soligenix
  • Onxeo
  • BioCryst Pharmaceuticals
  • miRagen Therapeutics
  • MedC Biopharma Corporation
  • And many others.

 

Request For Sample Page: https://www.delveinsight.com/sample-request/cutaneous-t-cell-lymphoma-ctcl-market

 

Cutaneous T-Cell Lymphoma Therapies are:

  • SGX301
  • Remetinostat
  • AFM13
  • Cobomarsen
  • Resminostat
  • Pembrolizumab
  • E7777
  • CD11301
  • And Many Others

 

Request For Sample Page: https://www.delveinsight.com/sample-request/cutaneous-t-cell-lymphoma-ctcl-market

 

Key Topics Covered

1. Key Insights

2. Cutaneous T- Cell Lymphoma (CTCL) Market Overview at a Glance

3. Cutaneous T- Cell Lymphoma (CTCL) Disease Background and Overview

4. Cutaneous T- Cell Lymphoma (CTCL) Epidemiology and Patient Population

5. Cutaneous T- Cell Lymphoma (CTCL) Incident Population in 7MM

6. Cutaneous T- Cell Lymphoma (CTCL) Country Wise-Epidemiology

7. Treatment Algorithm, Current Treatment, and Medical Practices

8. Unmet Needs

9. Cutaneous T- Cell Lymphoma (CTCL) Marketed Drugs

10. Cutaneous T- Cell Lymphoma (CTCL) Emerging Therapies

11. Cutaneous T- Cell Lymphoma (CTCL) 7 Major Market Analysis

12. The United States Market Outlook

13. EU-5 Countries: Market Outlook

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market